Introduction
============

Colorectal cancer (CRC) is the third most common neoplastic disease in males, after lung and prostate cancer, and the second in females after breast cancer; furthermore, it is the fourth most frequent neoplastic cause of mortality after lung, stomach, and liver cancer ([@b1-ol-0-0-4798]). Excellent results have been obtained in the management of non-invasive and early-stage invasive disease in recent times, particularly due to improvements in multidisciplinary endoscopic, surgical, radiotherapeutic and medical oncology protocols. Conversely, progression in the setting of advanced and/or metastatic disease have been less consistent, and relative survival rates remain low ([@b1-ol-0-0-4798]--[@b3-ol-0-0-4798]). The role of tumour genetics in this setting is extremely important, particularly in the development of novel therapeutic strategies, based on specific molecular targets.

The most relevant results of 'targeted therapies' have been obtained thanks to the comprehension of the pathophysiological mechanisms involving the epidermal growth factor receptor (EGFR)-RAS cascade ([@b4-ol-0-0-4798]). The EGFR is a trans-membrane protein for epidermal growth factor that mediates its functions through the activation of the RAS protein family members (HRAS, KRAS, and NRAS) ([@b4-ol-0-0-4798]). Activated RAS proteins promote cell proliferation through a number of mechanisms, including constitutive stimulation of mitogen activated protein-kinases (MAPK) ([@b4-ol-0-0-4798]). EGFR-targeted agents that compete with EGF for binding the receptor have been employed in clinical practice, in order to inhibit cell proliferation ([@b5-ol-0-0-4798]). Oncogenic RAS activation is a result of specific mutations into the kinase regions of the genes, producing a constitutive induction of the phosphorylating function of the RAS proteins, which in turn promotes neoplastic proliferation and drastically reduces the effect of anti-EGFR therapies ([@b5-ol-0-0-4798],[@b6-ol-0-0-4798]). Indeed, mutations in *KRAS* have been extensively demonstrated to act as a predictor of the absence of clinical response to EGFR-targeted agents ([@b7-ol-0-0-4798]--[@b9-ol-0-0-4798]). Nevertheless, the significance of *KRAS* mutation as a global prognostic factor of disease progression and survival in patients with colorectal cancer is not clear. Previous studies have reported a statistically significant reduction in disease free (DFS) and overall survival (OS) in the presence of *KRAS* mutations ([@b10-ol-0-0-4798],[@b11-ol-0-0-4798]). Nevertheless, such findings were not confirmed in another study ([@b12-ol-0-0-4798]). The aim of the present study was to evaluate the significance of the *KRAS* mutational status in terms of time to first metastasis (TTM) and OS in a cohort of Sardinian patients with CRC.

Materials and methods
=====================

### Study population

A total of 551 patients with a histologically proven diagnosis of metastatic CRC at the time of enrolment, who were treated and followed-up at healthcare institutions across Sardinia, were included into the study. To avoid any bias, CRC patients were consecutively collected from March 2009 to July 2014; they were included regardless of age at diagnosis and disease characteristics. Cases associated with syndromic colorectal polyposis were excluded.

Sardinian origin was ascertained in all cases through genealogical studies; for all patients, place of birth of their parents and grandparents was assessed in order to assign their geographical origin within the island. Clinical and pathological features for the assessment of the disease stage at diagnosis as well as of the onset age and tumor anatomical location were confirmed by medical records and/or pathology reports. Follow-up and prognostic information were obtained from clinical records at the institutions participating to the study and the records from the local cancer registry. The local cancer registry collects data on neoplastic diseases affecting inhabitants in north Sardinia, through the local hospitals and health care services as with other registries (e.g., death registries), and forms part of a wider network of tumour registries coordinated by the Italian Association for Tumour Registries (Associazione Italiana Registri Tumori, AIRTUM).

All patients gave written informed consent for *KRAS* mutation analysis prior to tissue sample collection. The study was reviewed and approved by the ethics committee of the Local Health Agency of Sassari (Sassari, Italy).

### KRAS mutational analysis

Formalin-fixed paraffin embedded tissue samples from CRC patients were obtained from the archives of the Institutes and Services of Pathology participating in the study. Tissue samples were estimated to contain at least 70% neoplastic cells by light microscopy. Subsequently, all tumor tissues were processed at the laboratory of the Institute of Biomolecular Chemistry of Sassari; genomic DNA was isolated from tissue sections using a standard protocol and DNA quality assessed for each specimen. In particular, paraffin was removed from formalin-fixed paraffin-embedded (FFPE) samples by treatment with Bio-Clear (Bio-optica, Milan, Italy) and DNA was purified using the QIAamp DNA FFPE Tissue kit (QIAGEN Inc., Valencia, CA, USA).

The coding sequence and splice junctions of exons 2, 3, and 4 of the *KRAS* gene (where all pathogenic mutations occur), were screened for mutations by direct automated sequencing. Briefly, polymerase chain reaction (PCR) was performed on 25--50 ng of isolated genomic DNA in a 9,700 Thermal cycler (Life Technologies/ThermoFisher Scientific, Inc., Waltham, MA, USA); all PCR products were directly sequenced using an automated fluorescence-based cycle sequencer (ABIPRISM 3130, Life Technologies, ThermoFisher Scientific Inc.), as previously described ([@b13-ol-0-0-4798]). Primer sequences and protocols for PCR-based assays were designed and optimized in our laboratory; they are available upon request.

### Statistical analysis

Statistical analysis was performed using the statistical package SPSS version 7.5 for Windows (SPSS, Inc., Chicago, IL, USA) and Pearson\'s Chi-Squared test. Descriptive analysis for qualitative variables was conducted using proportions. P≤0.05 was considered to indicate a statistically significant difference. Furthermore, a Cox proportional hazards regression model using the Newton-Raphson algorithm was used to determine the impact of the following variables on survival: Gender, age, *KRAS* status and mutation codons.

Results
=======

Paraffin-embedded tumour tissues from a total of 551 patients with invasive CRC and originating from Sardinia island were screened for mutations in the *KRAS* gene. The median age of the patients was 65 years (range, 32--87 years), with a preponderance of males (328 men; 59.5%). Considering the location of the primary tumour, the left colon was most frequently involved \[left colon, 263 (48%); right-transverse colon, 181 (29%); rectum, 107 (19%)\] ([Table I](#tI-ol-0-0-4798){ref-type="table"}). Considering the disease stage at the time of diagnosis, the majority of patients presented without distant metastases \[55%; AJCC stages II and III, 162 (29.4%) and 140 (25.4%), respectively\] ([Table I](#tI-ol-0-0-4798){ref-type="table"}).

The full coding sequences and intron-exon junctions of the *KRAS* gene were sequenced in the entire series of 551 CRC patients. Overall, *KRAS* mutations were detected in 183 (33%) patients; 3 patients presented with coexistence of 2 *KRAS* mutations in the same primary tumor tissue ([Table II](#tII-ol-0-0-4798){ref-type="table"}). In terms of the gene positions of the identified 186 *KRAS* mutations, 125 (67%) of the mutations were located in codon 12, 36 (19.4%) were located in codon 13, and 18 (9.7%) were in codon 61 ([Fig. 1](#f1-ol-0-0-4798){ref-type="fig"}). The remaining mutations (7; 3.8%) were detected in uncommonly-affected codons of the *KRAS* gene ([Table II](#tII-ol-0-0-4798){ref-type="table"} and [Fig. 2](#f2-ol-0-0-4798){ref-type="fig"}). All *KRAS* mutations detected in the present study have been previously reported in the Human Gene Mutation Database (HGMD) of the Institute of Medical Genetics in Cardiff (<http://archive.uwcm.ac.uk>) and in the Catalogue Of Somatic Mutations In Cancer (COSMIC) of the Wellcome Trust Sanger Institute (<http://www.sanger.ac.uk/genetics/CGP/cosmic/>).

No statistically significant correlations were identified between the presence of *KRAS* mutations and gender, age at diagnosis, anatomical location of primary CRC, and AJCC stage of the disease at the time of diagnosis ([Table I](#tI-ol-0-0-4798){ref-type="table"}).

Using the Cox proportional hazards model, no prognostic values of *KRAS* mutations were identified for the TTM \[Odds Ratio (OR) 1.18, 95% CI 0.81--1.72, P=0.198\] or OS (OR 1.28, 95% CI 0.87--1.90, P=0.107) ([Table IIIA](#tIII-ol-0-0-4798){ref-type="table"}). When patients were stratified by both *KRAS* mutational status and gender, significantly improved TTM was observed for *KRAS*-mutated male cases (OR 1.58, 95% CI 0.96--2.60, P=0.035) ([Table IIIA](#tIII-ol-0-0-4798){ref-type="table"}; [Fig. 3A](#f3-ol-0-0-4798){ref-type="fig"}). Conversely, no difference in OS was observed between the two genders according to the occurrence of *KRAS* mutations ([Fig. 3B](#f3-ol-0-0-4798){ref-type="fig"}). Considering the gene positions of the identified *KRAS* mutations, no correlation with both the TTM ([Table IIIB](#tIII-ol-0-0-4798){ref-type="table"}) and OS (data not shown) was observed.

Discussion
==========

The *KRAS* proto-oncogene encodes a guanosine triphosphate (GTP)/guanosine diphosphate (GDP) binding protein (21 kDa), which regulates cell responses to a number of extracellular stimuli ([@b14-ol-0-0-4798]). Activating mutations in *KRAS* are dominant and generally appear in an early stage of CRC carcinogenesis (early-intermediate adenoma), maintaining a stable incidence in higher stages (late adenomas and carcinomas). Approximately 30--50% of CRC patients have KRAS mutations, and they are associated with poor responsiveness to anti-EGFR antibody therapies ([@b7-ol-0-0-4798]--[@b10-ol-0-0-4798],[@b15-ol-0-0-4798]). In the present study, 33% of the patients with CRC harboured a mutation in the *KRAS* gene. In accordance with previous reports, no statistically significant differences in the distribution of these mutations between genders, ages, disease locations, and stages were found in our cohort ([@b10-ol-0-0-4798]). In addition, the mutation sites within the gene were similar to those widely reported, with the codons 12 and 13 affected in \~80% of cases. Notably, 7 mutations were identified in uncommonly-affected codons ([Table II](#tII-ol-0-0-4798){ref-type="table"}). In total, 6 of these mutations were single base substitutions and one was an insertion between codons 12 and 13 (c.35_36insAGCTGG). *KRAS* insertions have been sporadically reported among CRC patients; overall, biological and clinical significance of such mutations is yet to be defined ([@b16-ol-0-0-4798]).

Despite knowledge of the effect of *KRAS* mutations in predicting lack of response to anti-EGFR therapy, the global impact of such mutations on OS and DFS in CRC patients remains controversial. In 1994, Tanaka *et al* ([@b17-ol-0-0-4798]) published the first valuable article on such a topic. The authors examined a cohort of 15 KRAS mutations occurring in 62 Japanese patients using an oligonucleotide hybridization technique, and found that *KRAS* mutation was an independent prognostic factor in a multivariate analysis ([@b17-ol-0-0-4798]). In the same year, Morrin *et al* ([@b18-ol-0-0-4798]) published a less extensive study on 52 CRC patients with 14 *KRAS* mutations, without evidence of any prognostic impact. One year later, Bennett *et al* ([@b19-ol-0-0-4798]) published their series of 157 Dukes\' stage B CRCs with mutations in codon 12, which were analysed by PCR and direct sequencing. The authors failed to demonstrate a predictive role for survival of *KRAS* mutations by log rank and multivariate analysis ([@b19-ol-0-0-4798]). Lee *et al* ([@b20-ol-0-0-4798]) subsequently reported a series of 64 Chinese patients; 38 patients were Dukes\' stage A and B, and 26 patients were Dukes\' stage C and D ([@b20-ol-0-0-4798]). Log rank tests identified that *KRAS* gene mutation and Dukes\' stage were associated with patients\' survival; furthermore, patients with *KRAS* mutations were found to have shorter survival times into the subgroup with Dukes\' stage A and B, but not in that with stages C and D ([@b20-ol-0-0-4798]). Pricolo *et al* ([@b21-ol-0-0-4798]) published their series on 70 Dukes\' stage C patients analysed by topographic genotyping, and found a 36% *KRAS* mutations that did not affect significantly the risk of mortality or the 5-year survival rate. In 1998, Kressner *et al* ([@b22-ol-0-0-4798]) published their results on a series of 62 KRAS mutations found by temporal temperature gradient gel electrophoresis among 191 Swedish CRC patients; again, *KRAS* mutations had no relevant prognostic importance ([@b22-ol-0-0-4798]). Conversely, Andreyev *et al* ([@b23-ol-0-0-4798]) performed the RASCAL study, a large cohort collaborative report which indicated that *KRAS* mutations-especially those of codon 12 were associated with increased risk of relapse or mortality. More specifically, the subsequent RASCAL II study, which involved 3,498 patients with CRC, indicated that only the substitution of glycine to valine on codon 12 had a significant influence on OS, particularly among patients with Dukes\' stage C carcinomas ([@b10-ol-0-0-4798]). These studies did not indicate any prognostic role for mutations in codon 13 of the *KRAS* gene. Certain authors consider that the prognostic value for the KRAS^G12V^ mutation in the RASCAL study may represent the result of methodological limitations due to the retrospective recollection of patients enrolled in different studies using 3 different mutational tests, and possible nonrandom systemic errors that may affect meta-analysis of such datasets ([@b24-ol-0-0-4798]).

In 2000, Samowitz *et al* ([@b25-ol-0-0-4798]) published their results on a large cohort including 100 KRAS^codon\ 13^ mutations identified by PCR and direct sequencing-in 1,413 CRC patients from California and Utah. The authors found that generally *KRAS* mutations were not associated with increased cancer-associated mortality in their cohort; nevertheless, mutations in codon 13 were associated with a 40% greater likelihood of dying, although the significance of such finding was borderline when adjusted for age and disease stage ([@b25-ol-0-0-4798]). Other valuable studies on the prognostic significance of *KRAS* mutations in CRC patients were performed during the 2000s; the most relevant series were those of Ogino *et al* ([@b26-ol-0-0-4798]) in the USA, Zlobec *et al* ([@b27-ol-0-0-4798]) in Switzerland, Winder *et al* ([@b28-ol-0-0-4798]) in Austria, and Bazan *et al* ([@b29-ol-0-0-4798]) in Italy. Ogino and collegues performed an evaluation of the independent effect of the CpG island methylator phenotype (CIMP), microsatellite instability (MSI), *KRAS* and *BRAF* mutations on the prognosis of 649 patients with I--IV stage CRC. The study did not identify a relevant role of the *KRAS* mutations on prognosis, but the authors provided evidence that CIMP-high appears to be an independent predictor of a low CRC-specific mortality, while *BRAF* mutations are associated with a high CRC-specific mortality ([@b26-ol-0-0-4798]). By contrast, in their combined analysis of specific *KRAS* gene alterations, BRAF^V600E^ status, and MSI, Zlobec *et al* ([@b27-ol-0-0-4798]) found that specific *KRAS* mutations act as informative prognostic factors in both sporadic and hereditary CRC; an algorithm including all these alteration may identify sporadic CRC patients with poor clinical outcome. Winder *et al* ([@b28-ol-0-0-4798]) in their Austrian series of 342 cases were the first to report an improved OS in patients with KRAS^codon\ 13^ mutations compared to those with wild-type genes, further suggesting that different types of *KRAS* mutations may be differently associated with OS in patients with CRC ([@b28-ol-0-0-4798]). Finally, a multivariate analysis by Bazan *et al* ([@b29-ol-0-0-4798]) in a series of 160 cases found that KRAS^codon\ 13^ mutations were associated with poorer OS but not DFS ([@b29-ol-0-0-4798]).

It is evident that the global prognostic impact of *KRAS* mutations in patients with colorectal cancer remains unclear. The discrepancy of results among the studies mentioned may be explained on the basis of the relevant number of confounding and heterogeneity factors. The most frequent are: a) Heterogeneity of the study populations; b) discrepancies in study design and methodology; c) strategies for detecting *KRAS* mutations (including type of tissue samples i.e., primary or metastatic tumours); d) presence of underlying predisposing conditions (i.e. ulcerative colitis); e) variability of the staging systems (Dukes, AJCC, different editions); and f) clinical management and treatments employed.

Ren *et al* ([@b30-ol-0-0-4798]) have recently published a well-designed review and meta-analysis on the impact of *KRAS* mutations on OS in CRC patients, with the aim to reduce biases as those mentioned above ([@b30-ol-0-0-4798]). The authors performed a careful selection of 23 articles published from 1992, including 25 sets of data with 4,687 patients and 1,364 (29%) *KRAS*-mutated cases. Among them, 9 indicated that *KRAS* mutations were associated with worse prognosis, 15 failed to demonstrate any statistically significant association between such mutations and prognosis, and, finally, one data set identified an improved survival rate for patents with CRC and *KRAS* mutations ([@b30-ol-0-0-4798]). Globally, the authors found that *KRAS* mutations were not associated with CRC prognosis, either before or after adjustment for the effect of publication bias. Notably, the authors found that *KRAS* mutations in codon 13, and the technique of mutation detection (PCR-RFLP or PCR-SSCP, followed by sequencing) were associated with poorer OS; nevertheless, the authors considered that sample size may have not enough statistical power to accurately detect the association between *KRAS* mutations and survival ([@b30-ol-0-0-4798]).

In the present study, a clear association between occurrence of *KRAS* mutations and TTM or OS was not demonstrated in the entire series of 551 CRCs. When patients were stratified by both *KRAS* mutational status and gender, again, no significant differences in OS were identified, but a significantly improved TTM was observed for *KRAS*-mutated male cases. This finding is particularly notable, as the present study is the first to describe it in a series with a consistent number of CRC patients. Furthermore, TTM was determined which in our opinion better describes the biological events of CRC evolution in comparison with disease free survival (DFS) which better describes the impact of therapies on the progression of the disease.

On this regard, Samowitz *et al* ([@b25-ol-0-0-4798]) suggested that male patients are more likely to present transition mutations and G→A mutations due to different lifestyle factors, including alcohol and tobacco use, or dietary habits, which men and women are differently exposed to. In addition, the hormonal status has been involved in the pathogenesis of CRC through its impact on bile production and composition, bowel transit times, and bacterial metabolism ([@b25-ol-0-0-4798],[@b31-ol-0-0-4798]). A smaller increase in mortality in patients with transition mutations has been previously reported, while the variant with the higher likelihood of mortality was the G→A mutation at the codon 13 ([@b25-ol-0-0-4798]). The latter finding was also observed by Cerrottini *et al* ([@b32-ol-0-0-4798]). These data evidence that male patients may harbour less aggressive *KRAS* mutations, and this may explain the findings of the present study; nevertheless, it is not clear why this effect is limited to the initial progression as metastatic disease and does not affect OS. Unfortunately, the issue is not adequately studied in the current literature, and further well-designed studies are necessary to improve the understanding of such a specific prognostic variation in subgroups of patients with *KRAS* mutations.

The data presented in the current study suggest that *KRAS* mutations are not generally associated with TTM and OS in patients with CRC. Nevertheless, an improved TTM was observed in male patients with CRC harbouring *KRAS* mutations. Such a finding may be associated with the specific types of *KRAS* mutations observed in males and females as consequence of exposure to different lifestyle factors. Further well-designed studies are necessary to confirm such findings.
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###### 

Distribution of mutations according to the characteristics of colorectal cancer patients.

  Characteristic               No. (N=551)   *KRAS* mutations (%)   P
  ---------------------------- ------------- ---------------------- -------
  Gender                                                            
    Male                       328           103 (31)               0.654
    Female                     223             80 (36)              
  Tumor site                                                        
    Right-transverse colon     181             62 (34)              0.933
    Left colon                 263             85 (32)              
    Rectum                     107             36 (34)              
  Disease stage at diagnosis                                        
    Stage II                   162             50 (31)              0.247
    Stage III                  140             47 (34)              
    Stage IV                   249             86 (35)              
  Age, years                                                        
    \<50                         51            18 (35)              0.788
    50--59                     122             48 (39)              
    60--69                     200             64 (32)              
    70+                        178             53 (30)              

###### 

Unusual *KRAS* mutations found in the cohort of the present study.

  Amino acid mutation             DNA mutation                No. cases
  ------------------------------- --------------------------- -----------
  Mutations in uncommon codons                                
    p.G12_G13insAG                c.35_36insAGCTGG            1
    p.E49K                        c.145G\>A                   1
    p.A59E                        c.176C\>A                   1
    p.K117N                       c.351A\>T                   1
    p.A146T                       c.436G\>A                   3
  Coexistent multiple mutations                               
    p.G12D+p.Q61H                 c.35_36GT\>AC + c.183A\>C   1
    p.G12D+p.Q61L                 c.35_36GT\>AC + c.182A\>T   1
    p.G13V+p.Q61H                 c.38G\>T + c.183A\>C        1

###### 

Correlation between *KRAS* mutational status and survival.

  A, *KRAS* mutation status *in toto*                                                  
  ------------------------------------- --------- -------------- --------------------- -------
  TTM                                                                                  
    *KRAS* status                       1.187     0.816          1.726                 0.198
    Female and *KRAS* status            0.799     0.444          1.439                 0.254
    Male and *KRAS* status              1.583     0.962          2.606                 0.035
  OS                                                                                   
    *KRAS* status                       1.286     0.874          1.903                 0.107
    Female and *KRAS* status            1.151     0.825          2.766                 0.100
    Male and *KRAS* status              1.141     0.679          1.935                 0.345
                                                                                       
  B, *KRAS* codon-specific mutations                                                   
                                                                                       
                                                                 Confidence interval   
                                                                                       
  Parameter                             P-value   Hazard ratio   Lower                 Upper
                                                                                       
  TTM                                                                                  
    Gender                              0.011     0.728          0.569                 0.931
    Age at diagnosis                    0.473     1.161          0.771                 1.750
    Codon 12 mutations                  0.907     1.037          0.559                 1.924
    Codon 13 mutations                  0.861     1.045          0.634                 1.721
    Other codon mutations               0.806     1.076          0.598                 1.935

TTM, time to first metastasis; OS, overall survival.
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